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Abstract
Purpose To improve preoperative risk stratification for pros-
tate cancer (PCa) by incorporating multiparametric MRI
(mpMRI) features into risk stratification tools for PCa,
CAPRA and D’Amico.
Methods 807 consecutive patients operated on by robot-
assisted radical prostatectomy at our institution during the
period 2010–2015 were followed to identify biochemical re-
currence (BCR). 591 patients were eligible for final analysis.
We employed stepwise backward likelihoodmethodology and
penalised Cox cross-validation to identify the most significant
predictors of BCR including mpMRI features. mpMRI fea-
tures were then integrated into image-adjusted (IA) risk pre-
diction models and the two risk prediction tools were then
evaluated both with and without image adjustment using
receiver operating characteristics, survival and decision curve
analyses.
Results 37 patients suffered BCR. Apparent diffusion coeffi-
cient (ADC) and radiological extraprostatic extension (rEPE)
from mpMRI were both significant predictors of BCR. Both
IA prediction models reallocated more than 20% of
intermediate-risk patients to the low-risk group, reducing their
estimated cumulative BCR risk from approximately 5% to
1.1%. Both IA models showed improved prognostic perfor-
mance with a better separation of the survival curves.
Conclusion Integrating ADC and rEPE from mpMRI of the
prostate into risk stratification tools improves preoperative
risk estimation for BCR.
Key points
• MRI-derived features, ADC and EPE, improve risk stratifi-
cation of biochemical recurrence.
• Using mpMRI to stratify prostate cancer patients improves
the differentiation between risk groups.
• Using preoperative mpMRI will help urologists in selecting
the most appropriate treatment.
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Introduction
Prostate cancer (PCa) is the most common non-cutaneous
malignancy affecting men in developed countries. The
recommended treatment for highly selected low-risk dis-
ease is active surveillance rather than radical therapy such
as radical prostatectomy (RP) or external beam radiation
therapy [1]. A major challenge in treating PCa is to iden-
tify all patients with intermediate- and high-risk disease
who need radical treatment while avoiding overtreatment
in the low-risk group.
Biochemical recurrence (BCR) after RP is a well-
established predictor for clinical recurrence and disease-
related mortality. Two-thirds of BCR occur early, within 2
years of RP [2]. BCR after RP is defined as an elevated serum
prostate-specific antigen (s-PSA) above 0.2 ng/ml after nadir
4–6 weeks after surgery [3]. BCR is highly dependent on the
stage of the disease, as well as on the level of surgical perfor-
mance. Pavlovich et al. found BCR rates of 1.8% for pT2N0/
Nx and 22.3% for pT3N0/Nx/N1 [4]. The cohort-dependent
differences in BCR rates led to a proposal for risk-adjusted
follow-up based on three risk levels of BCR: low, intermediate
and high [5].
Positive surgical margins (SM+), extraprostatic extension
(EPE), biopsy and postoperative Gleason scores have all been
reported as reliable predictors of BCR [6, 7]. Risk stratifica-
tion tools, such as the University of California San Francisco
Cancer of the Prostate Risk Assessment tool (CAPRA) and
D’Amico, are routinely used to advise patients for or against
radical therapy including surgery on the basis of preoperative
information. D’Amico is based on s-PSA, biopsy Gleason
score and clinical T stage on digital rectal examination
(DRE) [8], while CAPRA additionally takes into account pa-
tient age and the percentage of positive biopsy cores [9] and is
validated for European patients [10, 11].
During the last decade, multiparametric MRI (mpMRI)
of the prostate was introduced for detection and
localisation of PCa. Recent studies indicate that mpMRI
has a high diagnostic accuracy for detection of PCa [12,
13], can improve predictions of preoperative clinical no-
mograms, at least for locally advanced disease [14, 15],
and that mpMRI may both improve predictions of clinical
BCR nomograms [16–19] and improve risk stratification
for detection of significant PCa [20].
We aimed to improve the prognostic accuracy of the two
most widely used clinical prediction tools, CAPRA and
D’Amico, by including pertinent mpMRI features such as
apparent diffusion coefficient (ADC), radiological EPE
(rEPE) and tumour size into new, image-adjusted (IA) predic-
tion models.
Materials and methods
Patients
The study population comprised 807 prospectively en-
rolled consecutive patients that underwent robot-assisted
laparoscopic radical prostatectomy (RALP) for PCa at our
institution between 1 January 2010 and 31 December
2015. Patients with persistent elevated s-PSA after
RALP, follow-up of less than 180 days, MRI examination
performed at 3 T or at other institutions, or missing ob-
servations were excluded from analysis (Fig. 1). A total of
591 patients were eligible for analysis, of which 59 re-
ceived adjuvant radiation therapy. Preoperative s-PSA
measurements were all taken within 3 days prior to the
operation. s-PSA levels before the operation and at nadir
4–6 weeks after RALP were all analysed at the same
laboratory between 1 January 2010 and 30 June 2016.
The institutional review board approved this study, and
all patients gave their written consent.
MRI protocol
Eighty-seven per cent (591/680) of all patients with preoper-
ative mpMRI were examined using the same 1.5-T MR ma-
chine (Avanto; Siemens Medical Systems, Erlangen,
Germany) and scanning protocol (Table 1).
MRI interpretation
All mpMRI examinations of the prostate were retrospec-
tively read in random order by one radiologist (LR)
blinded to clinical information and outcomes, except that
the patients had been allocated to RP for PCa. The radiol-
ogist had more than 10 years’ experience of reading pros-
tate mpMRI, presently interpreting at least 800 examina-
tions per year. rEPE was assessed on the basis of the
criteria bulging, asymmetric capsule and capsule contour
deviations [21] using a Likert scale from 1 to 5, where 1 =
no presence of EPE, 2 = probably no presence of EPE, 3 =
uncertain of the presence of EPE, 4 = EPE probably pres-
ent, 5 = EPE definitely present. We threshold the scores at
4 or above indicating the presence of EPE. Receiver oper-
ating characteristics (ROC) for rEPE are shown in supple-
mentary Fig. S1.
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Fig. 1 STARD diagram detailing
the stepwise exclusion leading to
the study cohort
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Image processing
The radiologist identified the leading lesion with the highest
Prostate Imaging Reporting and Data System (PI-RADS)
score by using PI-RADSv1 (10) blinded to final histopathol-
ogy result. The lesion size was measured on axial T2W images
as well as the ADC value from a region of interest (ROI),
including 2/3 of the lesion on axial ADC maps. The radiolo-
gist did not use software for segmentation or sophisticated
processing tools.
Surgery
RALP was introduced as standard surgical treatment for PCa
at our institution in May 2009. Four surgeons performed all
the procedures. Extended lymph node dissection [22] was
performed in 357 of the 807 patients (44%) during the study
period.
Histopathology
Whole-mount step sections were taken from the prostatec-
tomy specimens at 5-mm intervals. The pathologists
outlined the presence and extent of tumour involvement
in drawings based on the histological sections of the entire
prostate and determined the presence of a pathologic index
tumour based on the International Society of Urological
Pathology (ISUP) consensus conference criteria [23].
The volume of the tumours was estimated using routine
pathologic measurements as previously described [24].
The presence of EPE and SM+ was noted in each patient.
In addition, all preoperative biopsy data that are part of the
CAPRA and D’Amico tools were included in the database,
including Gleason grade and score and the percentage of
positive biopsy cores. In accordance with the 2014 ISUP
consensus, Gleason grade scores were grouped into five
grade groups [25], grade groups being both simpler and
more robust [26].
Data and statistics
All data were collected in a custom-developed relational da-
tabase that maintained blinding of the independent observers
[27]. Observations from individual tables were re-aggregated
using Structure Query Language views. Statistical analyses
were then performed using R 3.3.1 [28] utilising the pack-
ages EpiR, survival, ROCR, DecisionCurve and hdnom.
Continuous variables were summarised by median and
mean values, and interquartile ranges. To evaluate predic-
tors of early BCR, we used Cox hazards backward step-
wise likelihood ratio methodology with the lowest Akaike
information criterion (AIC) [29]. In addition, we applied a
penalised Cox regression model with leave-one-out cross-
validation (LOOCV), using an elastic net to estimate the
linear effect of the predictors, optimised at the simplest
model that has comparable error (1 standard deviation) to
the best model given the uncertainty [30]. To compare the
performance of the prediction tools we used ROC and
DeLong’s test, survival analysis, decision curve analysis
and ANOVA. All statistical tests were applied at a signif-
icance level of 5% (two-sided).
Creating the IA model
The pre-existing risk groups defined by CAPRA/D’Amico
were assigned 1 point for low risk, 2 points for intermedi-
ate risk and 3 points for high risk. Stepwise backward like-
lihood ratio testing and LOOCV identified two common
mpMRI features, statistically significant by LOOCV,
namely ADC and rEPE. To weight the mpMRI features,
we ran an LOOCV analysis based on the full preoperative
and postoperative variables, creating the nomogram shown
in supplementary Fig. S2. In this nomogram, an ADC val-
ue less than 800 mm2/s added 55 points to overall risk
while rEPE+ equated to 60 points. We decided to weight
points for ADC measurement into four groups, based on
the upper and lower boundaries of interquartile range at
Table 1 Scanning protocol
Sequence Plane Repetition time/echo time (ms) Intersection gap (mm) Matrix Field of view (mm) Acquisition time
T2W Sag 3030/98 0.8 320 × 256 200 × 200 3:06 min
T2W Cor 3000/98 0.4 320 × 256 200 × 200 4:05 min
T2W Axial 4840/84 0.8 320 × 256 200 × 200 4:18 min
VIBE Axial 7.23/2.55 0.8 192 × 192 250 × 250 20 s
DWI (b50, 400, 800) Axial 3000/72 0.8 128 × 128 128 × 128 5:33 min
DWI (b1200) Axial 2800/83 0.6 128 × 128 250 × 250 2:23 min
DCE TWIST + C Axial 4.24/1.66 0.8 512 × 512 192 × 138 6:58 min
Sag sagittal, Cor coronal, T2W T2-weighted imaging, T1 T1-weighted imaging, VIBE volumetric interpolated breath-hold examination, DWI diffusion-
weighted images,DCE TWIST dynamic contrast-enhanced time-resolved interleaved stochastic trajectories sequence, iPAT 2 time resolution = 6.16 s, +
C with intravenous contrast
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650 mm2/s and 961 mm2/s of our cohort. We thus chose a
cut-off value of ADC at 800 mm2/s, being almost 150
mm2/s from each interquartile range. For simplicity, we
chose ADC value cut-off points at 650, 800 and 950
mm2/s, resulting in groups of almost equal size.
For our IA model, we therefore assigned 0 points for ADC
values at the level of upper quartile around greater than 950
mm2/s, + 1 point for 950–800 mm2/s and + 2 points for 799–
650 mm2/s, and finally + 3 points for ADC values below the
lower quartile at approximately less than 650 mm2/s. If rEPE
was present (score ≥ 4), 2 points were assigned; if rEPE was
not present (score ≤ 3), 0 points were assigned. The points
were added to the pre-existing risk group points (low = 1,
intermediate = 2, high = 3) assigned by CAPRA/D’Amico.
This results in an eight-point risk scale with 1–2 = low risk, 3–
5 = intermediate risk, 6–8 = high risk.
Results
Of the 591 patients included in the final analysis, 37
(6.3%) were identified with early BCR. Surgical margins
were positive in 90 patients (15.2%); 49 of these were
pT3 (33.8% of all pT3), while 41 were pT2 (9.2% of all
pT2). The median length of SM+ for pT2 and pT3 was
2.5 mm and 2.7 mm, respectively. Eighteen patients (3%)
had N+ disease and 51 (8.6%) patients received adjuvant
therapy. Additional patient characteristics are listed in
Table 2.
Backward stepwise likelihood ratio method based on pre-
and postoperative information reduced the number of
predicting variables from 11 to 6 (Table 3). Histopathology
grade group 3+, tumour size in histopathology and ADC were
statistically significant. The LOOCVmethod also reduced the
Table 2 Patient characteristics n = 591
Biopsy age (years) Median (IQ) 63.3 (59.4–66.1) D’Amico Low 126
Intermediate 370
cT stage (DRE) T1c 427 High 95
T2a 91
T2b 45 CAPRA score Low 139
T2c 17 Intermediate 358
T3a/b 11 High 94
Grade group (biopsy) GG 1 195
GG 2 256
GG 3 81
GG 4 47
GG 5 12
# Positive biopsy cores (%) Median (IQ) 36 (21–50)
mpMRI to RALP (days) Median (IQ) 28 (14–62) Size T2W (mm) Median (IQ) 18 (13–23)
MRI indicating EPE, Likert score ≥ 3 rEPE– 377 Size ADC (mm) Median (IQ) 17 (12–24)
rEPE+ 214 (36%)
Lowest ADC-value in visible tumour Median (IQ) 767 (650–961)
Operation age (years) Median (IQ) 63.6 (59.6–66.5) Grade group GG 1 78
GG 2 357
Operation s-PSA (ng/ml) Median (IQ) 8.4 (6.1–12.0) GG 3 113
GG 4 12
GG 5 31
pT stage (‘92 classification) T2a 27
T2b 24 (1) No tumour
T2c 395
T3a 104
T3b 15
T3c 26
EPE Not present 493
Present 98 (16.6%)
Follow-up (years) Median (IQ) 2.5 (1.5–3.7)
Biochemical recurrence 37 (5.4%)
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number of predicting variables to 6, where 4 of the 6 variables
from Table 3 were the same for both methods.
Predictions by both the risk stratification tools and respective
IA models and outcomes are summarised in Table 4. For the
CAPRA model, image adjustment moved 55 (39.6%) of the
low-risk patients into the intermediate-risk group and 2 (1.4%)
into the high-risk group. The IA model further moved 84
(23.5%) of the intermediate-risk patients into the low-risk group
and 21 (5.9%) into the high-risk group. In the CAPRA high-risk
group, the IA model moved 49 patients (52.1%) down to the
intermediate-risk group. Similar results were found for IA–
D’Amico (data not shown). The crude numbers and effect of
application of the IA model to CAPRA are shown in Fig. 2.
Despite allocating extra patients to the low-risk group, BCR
risk in the low-risk group decreased from 4.5–5% to 1.1% for
both models. Furthermore, both IA models reduced the number
of high-risk patients with a concomitant increase in the BCR risk
in the remaining high-risk patients.
ROC analysis (Fig. 3) as well as the supplementary decision
curve analysis (Fig. S3) confirmed that both IAmodels improved
prediction of BCR over the well-established stratification tools.
IA–CAPRAoutperformed the other preoperative risk assessment
tools as assessed byANOVAand the IAmodels had significantly
improved AUC, compared to the model they arrived from (p =
0.017, IA–CAPRA, and p = 0.008 IA–D’Amico). However, the
postoperative reduced model which includes histopathology and
surgical margins was still best (Fig. 3 and Fig. S3). Kaplan–
Meier curves for disease-free survival (Fig. 4) show a better
discrimination between the three risk groups for both IA–
CAPRA and IA–D’Amico as compared to the original risk strat-
ification tools. Examples of increased and decreased risk after
image adjustment are given in Figs. 5 and 6.
Discussion
The present study represents a new approach to integrating im-
aging features into preoperative risk stratification tools for risk of
recurrence. Instead of developing completely new risk prediction
tools predominantly based on imaging information, we sought to
retain the predictive power of two well-established preoperative
risk prediction tools for PCa, adding information from pertinent
imaging features weighted according to their relative risk contri-
bution. Our approach is essentially more conservative than set-
ting up a completely new model and helps to avoid overfitting
the prediction models to a given institutional cohort. This meth-
odology could also be applied to other cancers where imaging is
valuable e.g. breast cancer and rectal cancer [31, 32]. Dependable
pretreatment risk assessment is essential to select the most appro-
priate treatment, such as radical therapy for a patient with PCa.
This is a large retrospective cohort study showing a clear
benefit of integratingmpMRI features into well-established pre-
operative risk stratification tools, CAPRA and D’Amico, to
Table 3 Predictors of early BCR
by Cox hazards stepwise
backward likelihood ratio
P values
Unadjusted Adjusted Final model
Clinical + biopsy Palpable tumour on DRE 0.0418* 0.878
% positive biopsies 0.0030* 0.9476
Age at operation 0.884 0.8304
mpMRI Radiological EPE present 1.8e−06* 0.0703 0.055†
ADC value 2.95e−05* 0.0027* 0.001*
T2W size on mpMRI (mm) 0.0018* 0.0545 0.074†
Histopathology s-PSAwithin 3 days of operation 0.0123* 0.2148
Tumour size (ml) 3.97e−06* 0.0732 0.079†
Grade group 3+ 4.04e−06* 0.0001* 1.9e−04*
Histology EPE present (Yes/No) 0.0006* 0.7786
Pos. margins (Yes/No) 0.0002* 0.1023 0.137†
DRE Digital rectal examination, EPE extra prostatic extension, ADC apparent diffusion coefficient, T2W T2-
weighted
* p < 0.05 (two-sided). † Tumor size, radiological EPE and surgical margins were retained in the final model
despite p > 0.05
Table 4 Distribution of biochemical recurrence in the preoperative risk
stratification models
Low risk Intermediate risk High risk
BCR/total BCR/total BCR/total
CAPRA 7/139 5.0% 14/358 3.9% 16/94 17.0%
IA–CAPRA 2/163 1.2% 20/360 5.6% 15/68 22.1%
D’Amico 7/126 5.6% 18/370 4.9% 12/95 12.6%
IA–D’Amico 2/159 1.3% 14/366 3.8% 14/64 21.8%
Eur Radiol (2018) 28:1016–1026 1021
predict risk of BCR for PCa. In the 2016 revision of the
European Association of Urology (EAU) guidelines, mpMRI
was endorsed as a tool for assessing clinical tumour (cT) stage
in high-risk patients [1]. To our knowledge, the effect of this
new recommendation on the preoperative risk predictions has
not yet been validated. As an alternative approach to improving
preoperative risk stratification, we investigated the impact of
mpMRI features on risk stratification without altering the basis
for cT stage i.e. clinical findings on DRE. We decided not to
study the EAU criteria since utilising image information to
override cT stage would result in a T stage migration, which
would be difficult to adjust for when evaluating the effect of
integrating mpMRI features into new prediction tools. The use-
fulness of including preoperative information in addition to
postoperative information—until now the gold standard for risk
prediction—has been recently shown by Imnadze et al. [33].
Zhang et al. [17], using anMRI nomogram to predict BCR,
identified that patients with a low ADC, highMRI T stage and
ROC−analysis: CAPRA / D’Amico with and without IA−Modeling
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Fig. 3 Receiver operating
characteristics (ROC) comparing
original risk stratification tools
and the IA models. ROC curves
of the two major risk stratification
tools, CAPRA and D’Amico,
with and without image
adjustment; IA–CAPRA and IA–
D’Amico, including area under
the curve (AUC) and confidence
intervals (CI). The reduced
postoperative model includes all
risk predictors including
postoperative histopathology (see
text for details)
Fig. 2 Reallocation of patients
within CAPRA by using image
adjustment. Illustrating the
number of patients in each
category and effect (by colour/
arrows) of application of image
adjustment (IA) to one of the two
major risk stratification tools,
CAPRA. Numbers in squares are
the numbers of patients in each
category given for CAPRA
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high PI-RADS score had significantly higher risk of BCR by
univariate survival analysis. Further, given that ADC and PI-
RADS score were significant predictors of BCR in multivar-
iate Cox regression analysis, these findings are in line with our
study. Ho et al. [18] identified both mpMRI suspicion score
(low, moderate, high) and rEPE as predictors of BCR together
with Gleason score. The finding of rEPE and Gleason score as
independent predictors is in line with our study, but their
mpMRI suspicion score is related to the number of sequences
suggestive of cancer and is thus difficult to compare with the
ADC-threshold in our study.
Using our proposed IA models increased the number of
patients in the low-risk groups by 6 percentage points. At
the same time, risk of BCR in the low-risk groups was reduced
from approx. 5% to 1.1% using both IA prediction tools. This
could potentially reduce the number of patients selected for
radical treatment, offering them the alternative treatment strat-
egy of active surveillance (AS). This potential approach
should ideally be evaluated in a prospective randomised
non-inferiority trial based on IA–CAPRA comparing out-
comes between AS and radical treatment in the low-risk
group. The IA–CAPRA model also reduced the number of
patients in the high-risk group by 52% with a concomitant
increase in risk of BCR in the remaining patients from 17%
to 22%, leading to more specific predictions also at the high-
risk end of the spectrum.
Fig. 4 Kaplan–Meier curves illustrating risk stratification of biochemical recurrence (BCR) during the first 4 years of follow-up after prostatectomy for
the two major risk stratification tools, CAPRA and D’Amico, with and without image adjustment
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The differences between IA–CAPRA and IA–D’Amico
were marginal and performance almost equal, except for the
ANOVA analysis alone. Not all of the well-established nomo-
grams can be applied to any population [34]. If general per-
formance of a prognostic tool is low, this will pull down the
performance of the IA model.
The presented IA model is basically conservative and de-
pends on the primary risk stratification tools being used. The
mpMRI features, when applied, will only upgrade a low-risk
patient to the high-risk group if there is a huge mismatch
between mpMRI and preoperative clinical risk assessment. It
is worth noting that in our presented IA models, mpMRI fea-
tures including quantitative measurements of ADC can be
used to both upgrade or downgrade risk in a given patient,
in line with previous publications [35, 36]. Studies using qual-
itative PI-RADS criteria to predict postoperative Gleason
scores have similarly shown image-based up- and
downgrading [37, 38]. In a recent study by Park et al. [16]
utilising PI-RADS to predict BCR in a highly selected series
of 158 patients followed up for 2 years after operation at a
single institution, PI-RADS score of at least 4 indicated higher
risk of BCR in multivariate analysis. In contrast to Park et al.,
Fig. 5 Example of risk increase
(low to high) by IA models: a
ADC map, b high b value
(b1200), c T2W image, d
dynamic contrast-enhanced;
clinical information: s-PSA, 4.6;
biopsy Gleason grade, 3 + 4; 25%
pos. cores; CAPRA score =
2/D’Amico = intermediate. MRI
shows significant tumour on the
left side, ADC value = 629 mm2/s
and rEPE+, Likert score = 4.
Image adjusted to high risk.
Histopathology after
prostatectomy, pT3a; EPE = 4
mm; tumour volume = 1.5 ml;
Gleason grade, 3 + 4; neg.
margins, neg. lymph nodes; BCR
within 1 year after operation
Fig. 6 Example of risk reduction
(high to intermediate) by IA
models: a ADC map, b high b
value (b1200), c T2W image, d
dynamic contrast-enhanced;
clinical information: s-PSA, 9.8;
biopsy Gleason grade, 4 + 5; 90%
pos. cores; CAPRA score = 6,
D’Amico = high risk. MRI
demonstrates mildly restricted
diffusion on DWI, ADC value =
1006 mm2/s and rEPE–, Likert
score = 3. Image adjusted to
intermediate risk. Histopathology
after prostatectomy, pT3a; EPE =
0.5 mm; tumour volume = 3.9 ml;
Gleason grade, 3 + 4; neg.
margins; no BCR within 3 years
after operation
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our study employed a larger and more homogeneous cohort,
quantitative criteria for ADC, and LOOCV to assess the rela-
tive weighting of potential mpMRI predictive features.
A potential objection to the IA model may be that a clini-
cally or bioptically missed significant tumour will only be
partially corrected by the proposed IA model. In cases with
a significant mismatch between radiology and biopsies,
repeat biopsy under image guidance should be carefully
considered [39].
The present study has the following limitations. (i) Our
study was conducted at a single institution with a limited
number of patients. (ii) The observed frequency of BCR of
6.3% is lower than reported in previous studies [10, 11,
16–18]. This may partially be explained by our careful exclu-
sion of patients with persistent disease. (iii) The proportion of
patients with high risk in our cohort is lower than in other
series. However, the selection of patients was in accordance
with the guidelines at that time, and the results regarding sur-
gical margins were within the expected range. (iv) Differences
between scanners and imaging techniques will probably result
in slightly different cut-off points, presumably in a similar
range around 650, 800 and 950 mm2/s. However, Yoon et al.
[19] dichotomised at the ADC level of 746 mm2/s. The dif-
ferences in ADC cut-off from our study were most prob-
ably due to differences in scanner, b values and their high-
risk patient cohort. Zhang et al. [17] dichotomised at 950
mm2/s, with no information regarding why they chose
such a threshold.
Differences in ADC measurements between scanners can
be adjusted for with calibration using quantitative phantoms.
Increasing our patient cohort to patients scanned in multiple
scanners (n = 680) had no detectable effect on our IA model
results (analyses not shown). (v) Our model needs to be ex-
ternally validated in an independent cohort. Special consider-
ation was paid to statistical methods for estimates of predictors
with close attention to advice from expert biostatisticians.
In conclusion, integrating information from mpMRI of the
prostate into well-established clinical risk stratification tools
for BCR, CAPRA and D'Amico allows better predictions of
BCR and a better differentiation between risk groups, facili-
tating a more appropriate choice of follow-up at the different
risk levels. The improved risk stratification by mpMRI could
potentially result in a more appropriate choice of therapy i.e.
active surveillance versus radical therapy.
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